Zynrelef FDA Approval History
Last updated by Judith Stewart, BPharm on Jan 29, 2024.
FDA Approved: Yes (First approved May 12, 2021)
Brand name: Zynrelef
Generic name: bupivacaine and meloxicam
Dosage form: Injection
Company: Heron Therapeutics, Inc.
Treatment for: Postoperative Pain
Zynrelef (bupivacaine and meloxicam) is an extended-release, fixed-dose combination of the local anesthetic bupivacaine and the nonsteroidal anti-inflammatory drug (NSAID) meloxicam indicated for the management of postoperative pain.
- Zynrelef is indicated for use in adults for postsurgical analgesia for up to 72 hours after:
- soft tissue surgical procedures
- orthopedic surgical procedures
- foot and ankle procedures
- other orthopedic surgical procedures (e.g., total joint arthroplasty) in which direct exposure to articular cartilage is avoided.
- As Zynrelef contains the NSAID meloxicam, the product label carries a boxed warning for an increased risk of cardiovascular and gastrointestinal events.
- Common side effects include constipation, vomiting, and headache.
Development timeline for Zynrelef
| Date | Article |
|---|
| Jan 23, 2024 | Approval Heron Therapeutics Announces FDA Approval of Zynrelef Indication Expansion to Include Additional Orthopedic and Soft Tissue Procedures |
| Dec 9, 2021 | Approval Heron Therapeutics Announces FDA Approval of an Indication Expansion for Zynrelef for Postoperative Pain Management |
| May 13, 2021 | Approval FDA Approves Zynrelef (bupivacaine and meloxicam) for the Management of Postoperative Pain |
| Jan 21, 2021 | Heron Therapeutics Announces Publication of Results from EPOCH 1 Follow-On Study of HTX-011 in Patients Undergoing Bunionectomy Surgery |
| Nov 13, 2020 | Heron Therapeutics Resubmits New Drug Application to FDA for HTX-011 for the Treatment of Postoperative Pain |
| Jun 29, 2020 | Heron Therapeutics Receives Complete Response Letter for HTX-011 for the Management of Postoperative Pain |
| Feb 19, 2020 | Heron Therapeutics Announces FDA Extension of Review Period for NDA for HTX-011 for the Management of Postoperative Pain |
| Oct 28, 2019 | Heron Therapeutics Announces FDA Acceptance of New Drug Application Resubmission for HTX-011 for Management of Postoperative Pain |
| Oct 1, 2019 | Heron Therapeutics Resubmits New Drug Application to FDA for HTX-011 for the Management of Postoperative Pain |
| May 1, 2019 | Heron Therapeutics Receives Complete Response Letter For HTX-011 For The Management Of Postoperative Pain |
| Dec 31, 2018 | FDA Grants Priority Review Designation for Heron Therapeutics' NDA for HTX-011, a Non-Opioid for Postoperative Pain Management |
| Oct 31, 2018 | Heron Announces FDA Submission of HTX-011 NDA for Postoperative Pain Management |
| Mar 19, 2018 | Heron Announces Positive Topline Results From Pivotal Phase 3 Clinical Trials of HTX-011 in Bunionectomy and Hernia Repair |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Medical Disclaimer
